The Company's technologies are based on discoveries arising from research conducted at the University of Calgary. Dr. Coffey, VP Product Development for the Company was instrumental in these discoveries, and continues to be instrumental in the product development process.
The Company was formed in 1998, to explore the natural oncolytic capability of the reovirus, a virus that preferentially replicates in cells with an activated Ras pathway.
The product being developed by the Company may represent a novel treatment for certain tumor types and some cellular proliferative disorders. The Company’s product is a virus that is able to replicate specifically in, and hence kill, certain tumor cells both in tissue culture as well as in a number of animal models.
The Company’s product for human use, REOLYSIN®, is the reovirus. This virus has been demonstrated to replicate specifically in tumor cells bearing an activated Ras pathway. Activating mutations of Ras and upstream elements of Ras may play a role in greater than two thirds of all potential tumors.
| Contact Details: |
| 210, 1167 Kensington Crescent |
| NW Calgary |
| |
| AB T2N 1X7 |
| |
| Tel: | (403) 670-7377 |
| Fax: | (403) 283-0858 |
| Email: | dougballonc@aol.com |
| WWW: | www.oncolyticsbiotech.com/
|
| |
Press Releases on Oncolytics:
|
 |
| Oncolytics Biotech(R) Inc. Announces Terms of Unit Offering |
18th November, 2009 |
Oncolytics Biotech Inc. |
CALGARY, Nov. 18 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics" or the "Company") (TSX:ONC; NASDAQ:ONCY) announced today that it has entered into an underwriting
|
| Oncolytics Biotech(R) Inc. Announces Unit Offering |
17th November, 2009 |
Oncolytics Biotech Inc. |
CALGARY, Nov. 17 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics" or the "Company") (TSX:ONC; NASDAQ:ONCY) announced today that it is undertaking an overnight
|
| Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase I/II Trial Results in Advanced Solid Cancers with a Focus on the Head and Neck at the AACR-NCI-EORTC Meeting |
17th November, 2009 |
Oncolytics Biotech Inc. |
CALGARY, Nov. 17 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX:ONC, NASDAQ:ONCY) ("Oncolytics" or the "Company") today announced updated results from a Phase I/II U.K.
|
| Oncolytics Biotech(R) Inc. Collaborators to Present Updated Phase I/II Trial Results in Advanced Solid Cancers with a Focus on the Head and Neck at the AACR-NCI-EORTC Meeting |
16th November, 2009 |
Oncolytics Biotech Inc. |
CALGARY, Nov. 16 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX:ONC, NASDAQ:ONCY) ("Oncolytics" or the "Company") today announced that a poster presentation covering updated
|
| Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting |
6th November, 2009 |
Oncolytics Biotech Inc. |
CALGARY, Nov. 6 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX:ONC, NASDAQ:ONCY) ("Oncolytics" or the "Company") today announced updated results from a Phase II study of
|
Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.
This page has been viewed 635 times since April 2007, the link to the organisation's website has been followed 109 times
Recent Search Terms used to find this page: pharmaceutical companies in calgary | oncolytics | .
Search for more companies in NW Calgary
Search for more companies in
This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.BioPortfolio search results for
Oncolytics
